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Abstract 
Herein we describe a 8-years-old boy with chronic non-malignant non-infectious lymphadenopathy, failure 
to thrive, weakness, arthralgia, relapsing oral aftosis, and multiple non-invasive infections of the skin. 
Immunological and genetic studies revealed the expansion of  TCRαβ+ CD4-/CD8- T cells and a previously 
described heterozygous CASP10 mutation. This observation suggests that CASP10 mutations can lead to 
clinical manifestations that are not typical of Autoimmune lymphoproliferative syndrome.  
 
 
 
Introduction 
Autoimmune lymphoproliferative syndrome (ALPS) is a rare disorder characterized by defective FAS-
mediated apoptotic pathway of mature lymphocytes. The typical features are chronic non-malignant 
enlargement of spleen and lymph nodes, autoimmune manifestations, increased risk of lymphoma and 
expansion of TCRαβ+ CD4-/CD8- T cells.  
Different genetic defects have been described: the majority of patients affected has a germline or somatic 
mutation in FAS-mediated apoptotic pathway (ALPS–FAS and ALPS-sFAS); some patients harbor FAS-
ligand mutation (ALPS-FASL) or Caspase-10 gene mutations (ALPS-CASP 10). Most of these mutations are 
inherited in an autosomal dominant manner. However, cases with homozygous or compound heterozygous 
mutations have also been reported.  Some patients are clinically diagnosed, but don’t present any known 
mutations (ALPS-U) [1,2,3,4]. 
Based upon the diagnostic criteria, revised in 2009 (NIH International Workshop) [4], the definitive 
diagnosis of ALPS needs both required criteria (chronic non-malignant, non-infectious lymphoadenopathy 
and/or splenomegaly and elevated TCRαβ+ CD4-/CD8- T cells) and one of the primary accessory criteria 
(defective lymphocyte apoptotis and mutation in FAS, FASLG, CASP10)[4].  
Herein we describe a patient presenting with persistent lymphadenopathy, multiple non-invasive infections, 
skin involvement and recurrent fever for two years, associated with weakness, muscle pain and arthralgia. 
 
 
 
 
The case  
We report the case of a 8-years-old boy that came to our attention because of a recent history characterized 
by recurrent fever, associated with weakness, muscle pain, arthralgia, multiple episodes of oral aftosis, 
recurrent abdominal pain and multiple cervical  lymphadenopathy. In the previous year the patient presented 
twice an itchy rash of the trunk and limb, which spontaneously resolved, and relapsing episodes of balanitis. 
His family history was not informative; constitutional delay of growth was suspected because of failure to 
thrive since 2 years of age.  
In addition, at 18 months of age  Epstein Barr virus infection was diagnosed, while molluscum contagiosum 
infection was observed at 4 years old. Other infectious episodes include recurrent bronchitis with wheezing, 
hand-foot-mouth disease, relapsing pioderma infection of the scalp and inferior limbs, multiple warts of the 
hands and feet and an herpes-like rash of the facial skin at 7 years of age. 
The physical examination showed good general conditions, but persistent swelling of cervical lymph nodes. 
He performed an abdomen ultrasound, with detection of enlarged mesenteric lymph nodes persisting over 6 
months, without spleen enlargement.  
The laboratory tests revealed normal blood count, except for a moderate eosinophilia (about 550/uL),  
negative inflammatory markers, normal serum immunoglobulins and normal lymphocytes subpopulations, 
but increase of the TCRαβ+ CD4-/CD8- T cells up to 3.8%. Autoimmunity markers such as anti-nuclear 
antibodies, anti–dsDNA and ANCA were also negative (Table 1).   
Because of the expansion of the TCRαβ+ CD4-/CD8- T cell subset and the enlargement of multiple lymph 
nodes, we investigated FAS-mediated apoptosis, that turned out to be normal. Next we performed the genetic 
analysis of FAS, FASL, CASP10, CASP8, NRAS and KRAS genes that were associated with ALPS and 
ALPS-related disorders [1,2,3,4].   
In the patient we identified a CASP10 gene mutation: c.1216A>7 (ENST00000286186 gene sequence), 
resulting in aminoacid change at residue 406 (I406L).  The same CASP10 mutation  was identified in his 
mother, but the number of TCRαβ+CD4-/CD8-  T cells in her blood was normal (Table 1).    
 
Discussion 
Here we present the case of a patient with atypical clinical manifestations of ALPS and a CASP10 mutation, 
already reported in another patient, as causative of ALPS. [5].   
He presents chronic, non-malignant, non-infectious cervical and mesenteric lymphadenopathy, persisting for 
more than 6 months, expanded CD3
+
TCRαβ+CD4−/CD8− T cell subset, normal lymphocyte counts and 
heterozygous mutation of CASP10 (I406L). In addition, our patient has an history characterized by recurrent 
fever, associated with weakness, muscle pain, arthralgia, sometimes abdominal pain, recurrent oral aftosis, 
multiple non-invasive infections, especially balanitis, and recurring skin involvement.   
Zhu et al. [5] have reported that the I406L mutation of CASP10, as well as another missense mutation 
(L285F) [6], impair apoptosis of cells transfected with the CASP10 mutant alone and confer resistance to 
apoptosis by a dominant negative mechanism, when cotransfected with wild-type CASP10. Other genetic 
variants of CASP10, such as V410I and I446C mutations, were classified as polymorphic variants, because 
were found in 3.4% and 1.6% of healthy Caucasians [5] and do not have dominant negative effect in 
cotransfection assays [5, 6, 7, 8].  
The I406L mutation of CASP10 has been already described as causative of ALPS [5]. These patients 
presented lymphadenopathy, affecting mostly cervical lymph nodes, splenomegaly and autoimmune 
manifestations, such as autoimmune hemolytic anemia, idiopathic thrombocytopenia and malar rash 
exacerbated by sun. These manifestations were associated with impairment of T cell apoptosis, elevated 
immunoglobulins, appearance of autoantibodies (Coombs, anti-DNA, anti-dsDNA, anti-nuclear) and 
expansion of TCRαβ+CD4-/CD8- T cells.  
However, there is evidence that the CASP10 mutations may have incomplete penetrance, depending on the 
type of mutation, on possible association with mutations affecting other genes [5] and on unknown genetic 
and environmental modifiers. Moreover, Martinez–Feito et al. [9] have reported that genetic variations in 
CASP10 gene can interact with FAS gene mutations in the regulation of lymphocyte apoptosis and contribute 
in the determination of ALPS phenotype.  
Therefore, there are many evidence suggesting that ALPS cannot be considered a typical monogenic disease, 
but might arise from the concurrence of multiple genetic variants, affecting genes involved in the apoptotic 
pathway [9, 10,11].  
This is in accord with the broad heterogeneity of clinical manifestations among family members that share 
the same genotype, but mild or even absent clinical manifestations, such as mild splenomegaly, borderline 
cytopenias or low-titer of autoantibodies [1, 2, 5].  
Hence the clinical significance of a heterozygous mutation in a healthy relative of a patient with ALPS is yet 
not clear [1, 2, 9].  It’s difficult to predict penetrance based on genetic mutations.  
Even in our case, despite the mother of our patient has the same CASP10 mutation, she doesn’t display any 
clinical or immunological features of the disease, including a normal number of double negative T cells 
(TCRαβ+CD4-/CD8- T cells = 0.5%).  
In contrast to the report by Zhu et al., other Authors report that both I406L and L285F  do not affect CASP10 
activity and are not sufficient to cause the overt disease, since several mutated familial components are 
healthy [11].   
All these controversial observations may raise the question about the relevance of this mutation in the 
pathogenesis of ALPS, suggesting that other environmental or genetic factors are required for the 
development of ALPS-related disorders, especially in patients with atypical clinical manifestations.  It is 
likely that we need to improve our understanding about the physiopathological mechanisms beneath this 
syndrome, in order to enhance our clinical approach and treatment of the ALPS patients.   
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Table 1. Blood counts and immunological studies 
  
Blood count 
Leucocytes 
Neutrophils 
Lymphocytes 
Monocytes 
Eosinophils 
Erythrocytes 
Hb 
MCV 
Platelets 
 
4150/uL 
1370/uL 
1900/uL 
295/uL 
550/uL 
4.4 x 10
6
/uL 
12.9 g/dl 
85.4 fL 
268.000/uL 
 
Lymphocyte subpopulations 
CD3
+
 
CD3
+
CD4
+
 
CD3
+
CD8
+
 
CD19
+
 
CD3
-
CD16
+
CD56
+ 
CD3
+
TCR+CD4-CD8- 
 
79.1% 
27% 
27.8% 
10.5% 
9.8% 
3.8% 
 
Immunoglobulins 
Ig G 
IgA 
IgM 
IgE 
Anti-tetanus Antibodies 
anti-diphtheria Antibodies 
 
1220 mg/dl 
125mg/dl 
158 md/dl 
131KU/l 
Normal response 
 
 
Lymphocyte proliferation, 
FAS-mediated Apoptosis 
 
Normal response 
Normal response 
 
Autoantibodies 
 (Anti-nuclear antibodies,  
anti–ds DNA, ANCA) 
 
Negative 
 
FAS, FASL, CASP10, CASP8, 
NRAS, KRAS sequencing 
 
Mutation of CASP10 gene: 
c.1216A>7 (I406L) 
 
